Qian-hui Li
Guangzhou Key Laboratory Of Targeted Therapy For Gynecologic Oncology, Guangdong Provincial Key Laboratory Of Major Obstetric Diseases
Guangzhou, China
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
piRNA28846 has the potential to be a novel RNA nucleic acid drug for ovarian cancer.
Journal: NPJ precision oncology
Published: January 16, 2024
SNORA73B promotes endometrial cancer progression through targeting MIB1 and regulating host gene RCC1 alternative splicing.
Journal: Journal of cellular and molecular medicine
Published: March 10, 2023
SNORD60 promotes the tumorigenesis and progression of endometrial cancer through binding PIK3CA and regulating PI3K/AKT/mTOR signaling pathway.
Journal: Molecular carcinogenesis
Published: July 06, 2022
SNORA70E promotes the occurrence and development of ovarian cancer through pseudouridylation modification of RAP1B and alternative splicing of PARPBP.
Journal: Journal of cellular and molecular medicine
Published: April 29, 2022
Box C/D snoRNA SNORD89 influences the occurrence and development of endometrial cancer through 2'-O-methylation modification of Bim.
Journal: Cell death discovery
Published: April 20, 2022
Research progress on the tsRNA classification, function, and application in gynecological malignant tumors.
Journal: Cell death discovery
Published: September 24, 2021
Circ-NOLC1 promotes epithelial ovarian cancer tumorigenesis and progression by binding ESRP1 and modulating CDK1 and RhoA expression.
Journal: Cell death discovery
Published: May 20, 2020
circ-CSPP1 promotes proliferation, invasion and migration of ovarian cancer cells by acting as a miR-1236-3p sponge.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: November 26, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026